Mainboard · BSE and NSEDraft filed
Virupaksha Organics Limited IPO: dates, price band, lot size, objects of the issue
Get updates on this IPO
Dates, price band, allotment and listing notices by email, and new views from SEBI-registered research analysts on InsightPier by email.Too many attempts. Please wait a few minutes and try again.
Dates, allotment, listing and analyst views. Stop anytime.
By continuing you agree to the Terms and Privacy policy
Key facts
- Price band
- Not announced
- Lot size
- Not announced
- Lot amount at the upper band
- Not announced
- Issue size at the upper band
- ₹740.00 crore
- Bid dates
- Not announced
- Listing date
- Not announced
- Proposed exchanges
- BSE and NSE
Timeline (IST)
- Draft filedWed 8 Oct 2025 confirmedDRHP dated Mon 29 Sep 2025
- OpensDates to be announced
- ClosesDates to be announced
- AllotmentDates to be announced
- Refund and unblockDates to be announced
- ListingDates to be announced
Objects of the issue
| Object | Amount |
|---|---|
| Funding capital expenditure requirement for capacity expansion at the Expansion Units | ₹360.00 crore |
| Prepayment of all or a portion of certain outstanding borrowings availed by our Company | ₹195.00 crore |
| General corporate purposes | Not stated in the draft |
| Total | Not stated in the draft |
DRHP dated Mon 29 Sep 2025, page 122
Company and promoters
As described in the DRHP
We are a research and development (“R&D”) driven Indian pharmaceutical company engaged in the manufacture of active pharmaceutical ingredients (“APIs”) and intermediates.
DRHP dated Mon 29 Sep 2025, page 27
Promoters
- 9 individual promoters
DRHP dated Mon 29 Sep 2025, page 27
Shareholding
| Holding | Before the issue | After the issue |
|---|---|---|
| Promoters and promoter group | 59.84% | Not stated in the DRHP |
| Public | 40.16% | Not stated in the DRHP |
DRHP dated Mon 29 Sep 2025, page 116
Financials (restated)
| Item | March 31, 2025 | March 31, 2024 | March 31, 2023 |
|---|---|---|---|
| Revenue from operations | ₹811.71 crore | ₹765.99 crore | ₹644.84 crore |
| Profit after tax | ₹78.71 crore | ₹73.68 crore | ₹43.09 crore |
| Net worth | ₹456.62 crore | ₹275.31 crore | ₹209.71 crore |
| Total borrowings | ₹282.23 crore | ₹264.35 crore | ₹240.85 crore |
DRHP dated Mon 29 Sep 2025, page 78
Peer comparison (as in the DRHP)
| Name of the Company | Standalone / Consolidated | Total Revenue (₹ in million) | Face Value per Equity Share (₹) | Closing price as on September 26, 2025 | P/E | EPS (Basic and Diluted) (₹) Basic | EPS (Basic and Diluted) (₹) Diluted | RoNW (%) | NAV (₹ per share) |
|---|---|---|---|---|---|---|---|---|---|
| Our Company | Consolidated | 8,117.09 | 10.00 | NA | [●]* | 13.17 | 13.17 | 17.25 | 111.25 |
| Supriya Lifescience Limited | Standalone | 6,964.85 | 2.00 | 700.95 | 30.02 | 23.35 | 23.35 | 19.17 | 121.85 |
| Alivus Life Sciences Limited | Standalone | 23,868.84 | 2.00 | 933.45 | 23.62 | 39.63 | 39.52 | 17.24 | 229.92 |
| Divi's Laboratories Limited | Consolidated | 93,600.00 | 2.00 | 5690.30 | 68.95 | 82.53 | 82.53 | 14.67 | 562.70 |
| Laurus Labs Limited | Consolidated | 55,539.60 | 2.00 | 832.70 | 125.41 | 6.65 | 6.64 | 8.19 | 81.13 |
| Aarti Drugs Limited | Consolidated | 23,870.30 | 10.00 | 470.00 | 25.61 | 18.35 | 18.35 | 12.33 | 149.32 |
| Neuland Laboratories Limited | Consolidated | 14,768.37 | 10.00 | 13,954.45 | 68.83 | 202.74 | 202.74 | 17.08 | 1,186.90 |
Reproduced from the DRHP dated Mon 29 Sep 2025, page 147; InsightPier adds no figures
Risk factors
79 total- Most revenue comes from analgesic, anti-histamine and anti-fungal products; lower demand for them could hurt the business (DRHP page 37)
- Manufacturing units face regulator and customer inspections; quality problems could bring regulatory action (DRHP page 38)
- A large share of revenue comes from a few key customers; losing them could hurt results (DRHP page 39)
- Karnataka pollution board notices and closure directions for Unit 3 and Unit 6; shutdowns could hurt operations (DRHP page 39)
- Hazardous operations and materials could cause accidents, suspensions and liabilities (DRHP page 41)